Design, Structure−Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors⊥‡

2008 ◽  
Vol 51 (23) ◽  
pp. 7541-7551 ◽  
Author(s):  
Yan Shi ◽  
Doree Sitkoff ◽  
Jing Zhang ◽  
Herbert E. Klei ◽  
Kevin Kish ◽  
...  
Author(s):  
Christoph W. Müller ◽  
Montserrat Soler-Lopez ◽  
Christina Gewinner ◽  
Bernd Groner

2004 ◽  
Vol 14 (15) ◽  
pp. 4045-4050 ◽  
Author(s):  
Shawn M Bauer ◽  
Erick A Goldman ◽  
Wenrong Huang ◽  
Ting Su ◽  
Lingyan Wang ◽  
...  

mBio ◽  
2018 ◽  
Vol 9 (6) ◽  
Author(s):  
Pradeep Kumar ◽  
Glenn C. Capodagli ◽  
Divya Awasthi ◽  
Riju Shrestha ◽  
Karishma Maharaja ◽  
...  

ABSTRACTWe report GSK3011724A (DG167) as a binary inhibitor of β-ketoacyl-ACP synthase (KasA) inMycobacterium tuberculosis. Genetic and biochemical studies established KasA as the primary target. The X-ray crystal structure of the KasA-DG167 complex refined to 2.0-Å resolution revealed two interacting DG167 molecules occupying nonidentical sites in the substrate-binding channel of KasA. The binding affinities of KasA to DG167 and its analog, 5g, which binds only once in the substrate-binding channel, were determined, along with the KasA-5g X-ray crystal structure. DG167 strongly augmented thein vitroactivity of isoniazid (INH), leading to synergistic lethality, and also synergized in an acute mouse model ofM. tuberculosisinfection. Synergistic lethality correlated with a unique transcriptional signature, including upregulation of oxidoreductases and downregulation of molecular chaperones. The lead structure-activity relationships (SAR), pharmacokinetic profile, and detailed interactions with the KasA protein that we describe may be applied to evolve a next-generation therapeutic strategy for tuberculosis (TB).IMPORTANCECell wall biosynthesis inhibitors have proven highly effective for treating tuberculosis (TB). We discovered and validated members of the indazole sulfonamide class of small molecules as inhibitors ofMycobacterium tuberculosisKasA—a key component for biosynthesis of the mycolic acid layer of the bacterium’s cell wall and the same pathway as that inhibited by the first-line antitubercular drug isoniazid (INH). One lead compound, DG167, demonstrated synergistic lethality in combination with INH and a transcriptional pattern consistent with bactericidality and loss of persisters. Our results also detail a novel dual-binding mechanism for this compound as well as substantial structure-activity relationships (SAR) that may help in lead optimization activities. Together, these results suggest that KasA inhibition, specifically, that shown by the DG167 series, may be developed into a potent therapy that can synergize with existing antituberculars.


2000 ◽  
Vol 43 (11) ◽  
pp. 2135-2148 ◽  
Author(s):  
David R. Bolin ◽  
Amy L. Swain ◽  
Ramakanth Sarabu ◽  
Steven J. Berthel ◽  
Paul Gillespie ◽  
...  

2008 ◽  
Vol 18 (9) ◽  
pp. 2845-2849 ◽  
Author(s):  
James R. Corte ◽  
Tianan Fang ◽  
Donald J.P. Pinto ◽  
Wei Han ◽  
Zilun Hu ◽  
...  

2005 ◽  
Vol 48 (10) ◽  
pp. 3586-3604 ◽  
Author(s):  
Hiroshi Ueno ◽  
Katsuyuki Yokota ◽  
Jun-ichi Hoshi ◽  
Katsutaka Yasue ◽  
Mikio Hayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document